United States - English - NLM (National Library of Medicine)

a-s medication solutions - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets, usp are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets, usp increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets, usp are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)]. alendronate sodium tablets, usp are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)]. alendronate sodium tablets, usp are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)]. alendronate sodium tablets, usp are indicated for the treatment of paget's disease of bone in men and women. treatment is indicated in patients with page

United States - English - NLM (National Library of Medicine)

a-s medication solutions - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)] . alendronate sodium tablets are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's disease of bone who have al

United States - English - NLM (National Library of Medicine)

a-s medication solutions - alendronate sodium (unii: 2uy4m2u3ra) (alendronic acid - unii:x1j18r4w8p) - alendronate sodium tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). [see clinical studies (14.1).] alendronate sodium tablets are indicated for the prevention of postmenopausal osteoporosis [see clinical studies (14.2)] . alendronate sodium tablets are indicated for treatment to increase bone mass in men with osteoporosis [see clinical studies (14.3)] . alendronate sodium tablets are indicated for the treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density [see clinical studies (14.4)] . alendronate sodium tablets are indicated for the treatment of paget’s disease of bone in men and women. treatment is indicated in patients with paget's disease of bone who have al

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; microcrystalline cellulose - fonat is indicated for the treatment of: osteoporosis, including glucocorticoid-induced osteoporosis. fonat is indicated for the prevention of glucocorticoid-induced osteoporosis in those patients on long term corticosteroid therapy (see clinical trials, glucorticoid-induced osteoporosis). prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the mean for young adults (gender specific), or by: - the presence of osteoporotic fracture.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hovid berhad - alendronate monosodium salt trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - calcium carbonate, quantity: 1.25 g (equivalent: calcium, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; hypromellose; macrogol 8000; chlorophyllin-copper complex; titanium dioxide; carnauba wax - for the treatment of: ? osteoporosis in select patients where vitamin d and calcium supplementation is recommended,prior to treatment, osteoporosis must be confirmed by: ? the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by ? the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

actavis pty ltd - alendronate sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 140 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; hypromellose; butylated hydroxytoluene - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 70 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; mannitol; butylated hydroxytoluene; hypromellose - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmbio pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg) - tablet, effervescent - excipient ingredients: monosodium dihydrogen citrate; citric acid; sodium bicarbonate; sodium carbonate; acesulfame potassium; sucralose; flavour - binosto is indicated for the treatment of osteoporosis. prior to treatment, osteoporosis must be confirmed by the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by the presence of osteoporotic fracture